...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Zenith funding???

NBB - I can't argue with anything you said. As far as ZEL, I would have to think Pfizer has the lead with all they are doing together. They might only be small P2 trials but they are the ZEL lead molecule. I do think there has to be something in the cooking or they wouldn't be allowed to continue racking up debt like this with no money being raised. I have no clue what the trigger might be though. 

Share
New Message
Please login to post a reply